



Collaborator Overview: Evolyra Therapeutics

Evolyra Therapeutics is an emerging gene therapy company dedicated to developing transformative treatments for rare neuromuscular diseases. Headquartered in Richmond, Virginia, Evolyra is building a focused therapeutic pipeline around the goal of delivering disease-modifying genetic medicines for patients with devastating inherited muscle disorders, beginning with limb-girdle muscular dystrophies (LGMDs).

At the center of Evolyra's strategy is a clear scientific thesis: rare muscle diseases require more precise, better targeted gene delivery systems that can drive meaningful expression in skeletal muscle while minimizing off-target exposure. Evolyra is advancing this vision through AAV-based gene therapy programs designed to address the root genetic cause of disease rather than simply managing symptoms.

Evolyra's lead focus is on LGMD type 2C and LGMD type 2D, also referred to as LGMDR5 and LGMDR3. These disorders are severe, progressive, and life-limiting, and they remain areas of substantial unmet need with no curative therapy available today. Evolyra is positioning itself to change that landscape by developing therapies intended to restore functional protein expression in affected muscle tissue.

A key element of Evolyra's approach is its next-generation AAV platform, including the AAVMYO2 vector. This vector is engineered to favor skeletal muscle targeting while reducing liver tropism, an important design feature for improving tissue selectivity and potentially improving safety. That focus on biodistribution and tissue specificity places Evolyra squarely within the most advanced direction of modern gene therapy design.

Evolyra is also demonstrating operational momentum through its manufacturing and development partnerships. The company has publicly announced collaboration with Andelyn Biosciences for GMP AAV manufacturing and IND-enabling support, underscoring that its programs are moving beyond concept and into the rigorous development phase required for clinical testing. They have also entered a strategic collaboration with Puresyn to supply critical plasmid DNA starting material, further strengthening their position and broadening their execution model.

Taken together, Evolyra is a sharply focused, scientifically credible gene therapy company with a well-defined disease area, a rational vector engineering strategy, and the operational partnerships needed to advance toward the clinic. Evolyra has established the scientific, manufacturing, and development partnerships necessary to advance its programs.

Media Contact:

Evolyra Therapeutics:

Nicholas Johnson, MD

CEO

Nicholas.johnson@evolyratherapeutics.com

Puresyn:

Leslie M. Flynn

VP & General Manager

leslie@puresyn.com